FAVIPAC
- Category: ပိုးသတ်ဆေးများ
- UOM: Box of 2x10's Tablet
FAVIPAC
This medicine is prescription only medicine (POM ) and required under medical supervision .For the order request process, you need to attach the doctor's prescription.
ဤဆေးသည် ဆရာဝန်ညွှန်ကြားချက်နှင့်သာသောက်သုံးရမည့်ဆေးဖြစ်ပြီး ဆရာဝန်ညွှန်ကြားချက်လိုပါသည်။ အော်ဒါမှာယူမှုအတွက် ဆရာဝန်ဆေးညွှန်းစာကို Order request အဆင့်တွင် attach တွဲပေးရန်လိုပါသည်။
REMARK : Online order delivery may take from 3 to 5 days depend on area. For some areas in Yangon region such as North Dagon, South Dagon , Dagon Seikkan , Hlaing Thar Yar, Shwe Pyi Thar , Thanlyin , delivery will be around 1 week.
(မှတ်ချက် : အွန်လိုင်းမှတဆင့်မှာယူမှုများအတွက် အခမဲ့ပို့ဆောင်မှုမှာ ၃ ရက်မှ ၅ ရက်အတွင်းကြာမြင့်နိုင်ပါသည်။ အချို့ ဧရိယာများဖြစ်သည့် မြောက်ဒဂုံ ၊ တောင်ဒဂုံ ၊ ဒဂုံဆိပ်ကမ်း ၊ လှိုင်သာယာ ၊ ရွှေပြည်သာ ၊ သံလျှင် စသည့်မြို့များမှာမှာ တစ်ပတ်တရက်သာ ပို့ဆောင်သောကြောင့် ၁ ပတ်ခန့်ကြာမြင့်နိုင်ပါသည်။ )
FAVIPAC for the Treatment of mild to moderate COVID-19 Infection
FAVIPAC contains Favipiravir 200 mg and is indicated for the treatment of Novel coronavirus SARS-CoV-2 (Covid-19) infection or re-emerging influenza virus infections (limited to cases in which other anti-influenza virus agents are not effective or insufficiently effective).
Favipiravir (T-705) is a synthetic prodrug, first discovered while assessing the antiviral activity of chemical agents active against the influenza virus in the chemical library of Toyoma chemicals. A lead compound, A/PR/8/34, later designated as T-1105, and its derivatives were found to have antiviral activities.
Favipiravir is derived by chemical modification of the pyrazine moiety of T-1105. It has been approved in Japan for the management of emerging pandemic influenza infections in 2014. The molecule Favipiravir has been used in the treatment of antiviral activity and found to be effective since then. Favipiravir was first used against SARS-CoV-2 in Wuhan, at the very epicenter of the pandemic.
Then, as the pandemic spread to Europe, this drug received approval for emergency use in Italy, and currently has been in use in Japan, Russia, Ukraine, Uzbekistan, Moldova, and Kazakhstan. Approval has also recently been granted in Saudi Arabia and the UAE. Thereafter, Turkey, Bangladesh, and most recently Egypt have also seen recent commercial launches. In June 2020, favipiravir received the DCGI approval in India for mild and moderate COVID-19 infections.
As of the 23rd of July, 2020; there are 32 studies registered on clinicaltrials.gov to assess the utility of this drug in the management of COVID-19. One such drug is favipiravir, initially approved and marketed as an antiinfluenza agent in Japan. This drug has just received emergency approval by the Drug Controller General of India (DCGI).
Indication:
The use of this drug is considered only when there is an outbreak of novel or re-emerging influenza infections in which other anti-influenza virus agents are not effective or insufficiently effective, and the government has approved to use the drug as a countermeasure against such influenza viruses.
Dosage and Administration:
The dosage and duration of administration must be used by the direction of the physician.
Low dosage regime
The usual dosage of Favipiravir for adults is 1600 mg orally twice daily for 1 day followed by 600 mg orally twice daily for 4 days. The total administration period should be 5 days.
High dosage regime
The dosage of Favipiravir for adults is 1800mg orally twice daily for 1 day followed by 800mg orally twice daily for 4 days or dosage directed by the physician.
Product Development:
FAVIPAC (Favpiravir) was developed at R&D center of Pacific Medical Industries Ltd, Myanmar in form of tablets 200 mg with the knowledge, resources, and support of our API vendors against the comparator product “Avigan 200 mg Tablets”. The product has been developed with validated process approach to establish the manufacturing consistency and determine the critical process parameter and critical quality attributes and released under desired quality specification.
FAVIPAC is approved by Food and Drug Administration, Myanmar for the treatment of Covid-19. Considering the product dose criteria from the literature and research the product is packed in 2x 10’s Alu-Alu Blister.
References:
- 1) https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7467067/
- 2) https://www.biorxiv.org/content/10.1101/2020.07.07.191775v2.full.pdf
- 3) https://clinicaltrials.gov/ct2/show/NCT04400682
- 4) https://www.cdc.gov.tw/File/Get/ht8jUiB_MI-aKnlwstwzvw
- 5) https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7467067/
- 6) https://www.biorxiv.org/content/10.1101/2020.07.07.191775v2.full.pdf
- 7) https://clinicaltrials.gov/ct2/show/NCT04400682 8) https://www.cdc.gov.tw/File/Get/ht8jUiB_MI-aKnlwstwzvw
- 8) For all related reference link - www.favipac.blogspot.com
ဤ product သည် လတ်တလော တွင် online တွင်ရောင်းချခြင်းမရှိပါသဖြင့် အသေးစိတ်ဆက်သွယ်စုံစမ်းလိုပါက ဖုန်းနံပါတ် - ၀၉ ၇၆၂၂၄၄၄၄၁၊ ၀၉ ၇၆၂၂၅၅၅၅၁ ကိုဆက်သွယ်နိုင်ပါသည်။
| Favipiravir | 200 mg |
Precautions:
(1) No clinical study has been conducted to examine the efficacy and safety of Favipiravir with the approved dosage. The approved dosage was estimated based on the results of a placebo-controlled phase I/II clinical study in patients with influenza virus infection and the pharmacokinetic data from Japanese and overseas studies. Increase of plasma level of Favipiravir has been reported in patients with liver function impairment in pharmacokinetic study conducted outside of Japan.
(2) Although the causal relationship is unknown, psychoneurotic symptoms such as abnormal behavior after administration of anti-influenza virus agents including Favipiravir have been reported. For the treatment of children and minors, as a preventive approach in case of an accident due to abnormal behavior such as falling, patients/their family should be instructed that, after the start of treatment with anti-influenza virus agents, (i) abnormal behavior may be developed, and (ii) guardians and others should make an arrangement so that children/minors are not left alone for at least 2 days when they are treated at home. Since similar symptoms associated with influenza encephalopathy have been reported, the same instruction as above should be given.
(3) Influenza virus infection may be complicated with bacterial infections or may be confused with influenza-like symptoms. In case of bacterial infection or suspected to be bacterial infection, appropriate measures should be taken, such as administration of anti-bacterial agents.
Drug Interaction:
Favipiravir is not metabolized by cytochrome P- 450 (CYP), mostly metabolized by aldehyde oxidase (AO), and partly metabolized by xanthine oxidase (XO). The drug inhibits AO and CYP2C8, but does not induce CYP.
